Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $34.50 Average Price Target from Analysts

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) have been given an average recommendation of “Buy” by the six brokerages that are covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $34.50.

Several equities analysts recently commented on CAPR shares. Cantor Fitzgerald upped their target price on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a report on Thursday, January 2nd.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. lifted its stake in shares of Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in Capricor Therapeutics by 172.8% in the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 2,947 shares during the period. Virtus ETF Advisers LLC acquired a new position in Capricor Therapeutics during the fourth quarter valued at approximately $68,000. AlphaQuest LLC purchased a new stake in Capricor Therapeutics during the fourth quarter worth approximately $78,000. Finally, New York State Common Retirement Fund increased its position in shares of Capricor Therapeutics by 625.0% in the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 5,000 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock opened at $14.92 on Friday. The stock has a market capitalization of $678.41 million, a P/E ratio of -14.08 and a beta of 4.08. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40. The firm’s 50-day moving average is $14.17 and its two-hundred day moving average is $13.09.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.